ReviewJournal of hematology & oncology2019
Immune cell therapy for hepatocellular carcinoma.
Review in Journal of hematology & oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Efficacy and Safety of Cellular Immunotherapy by Local Infusion for Liver Tumor: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives.Vaccines · 2026Review
- Exosomal circRNAs in hepatocellular carcinoma: Implications for the development and therapeutic resistance of hepatocellular carcinoma (Review).International journal of oncology · 2026Review
- PLAURAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Applications of single-cell analysis in immunotherapy for lung cancer: Current progress, new challenges and expectations.Journal of advanced research · 2025Review
- Estrogen inhibits hepatocellular carcinoma progression dependent on HOXA11-AS/HOXA11.Translational oncology · 2025Article
- FMO2Journal for immunotherapy of cancer · 2025Article
- The role of immune regulation in HBV infection and hepatocellular carcinogenesis.Frontiers in immunology · 2025Review
- Evolution of Clinical Trials of Systemic Therapies for Hepatocellular Carcinoma Between 2005 and 2024: Based on ClinicalTrials.gov.Gastro hep advances · 2025Review
- Research trends of cellular immunotherapy for primary liver cancer: A bibliometric analysis.Human vaccines & immunotherapeutics · 2024Article
- Epigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy.Expert reviews in molecular medicine · 2024Review
- Natural killer (NK) cells-related gene signature reveals the immune environment heterogeneity in hepatocellular carcinoma based on single cell analysis.Discover oncology · 2024Article
- Integrative analysis of the role of theTranslational cancer research · 2024Article
- Reprogramming hematopoietic stem cell metabolism in lung cancer: glycolysis, oxidative phosphorylation, and the role of 2-DG.Biology direct · 2024Article
- Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma.Frontiers of medicine · 2024Article
- Liver metastases across cancer types sharing tumor environment immunotolerance can impede immune response therapy and immune monitoring.Journal of advanced research · 2024Article
- Harnessing CD8Clinical and translational medicine · 2024Review
- Article
- Macroscopic inhibition of DNA damage repair pathways by targeting AP-2α with LEI110 eradicates hepatocellular carcinoma.Communications biology · 2024Article
- Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy.World journal of gastrointestinal oncology · 2024Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the success of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells in clinical settings, the host immune system plays an important role in the recognition and targeting of tumor cells in cancer immunotherapy. As a result, there have been numerous advancements in immune cell therapy using human immune cells. However, recent evidence suggests that one type of immunotherapy alone is not effective for the treatment of cancer, particularly solid tumors. Thus, effective immunotherapy combinations, such as the combination of checkpoint inhibitors and immune cell therapy, are needed. This review focuses on hepatocellular carcinoma among other solid tumors and discusses the current status and future of immune cell therapy in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.